

Jonathan C Hsu, Mas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3124831/publications.pdf>

Version: 2024-02-01

129
papers

2,613
citations

257450

24
h-index

223800

46
g-index

133
all docs

133
docs citations

133
times ranked

3908
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of Super-Response to Cardiac Resynchronization Therapy and Associated Improvement in Clinical Outcome. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2366-2373.	2.8	252
2	Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk. <i>JAMA Cardiology</i> , 2016, 1, 55.	6.1	249
3	Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2475-2484.	2.8	220
4	Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2913-2923.	2.8	119
5	Atrial Fibrillation and Atrial Flutter in Human Immunodeficiency Virus-Infected Persons. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2288-2295.	2.8	85
6	Management of Arrhythmias in Cardiac Amyloidosis. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 351-361.	3.2	77
7	Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients. <i>Heart Rhythm</i> , 2006, 3, 1196-1201.	0.7	69
8	Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. <i>Journal of the American College of Cardiology</i> , 2021, 77, 861-871.	2.8	62
9	Cardiac Perforation From Implantable Cardioverter-Defibrillator Lead Placement. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 582-590.	2.2	60
10	Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS ₂ to the CHA ₂ DS ₂ -VASc Score for Thromboembolic Risk Assessment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	2.2	60
11	Randomized Trial of Conventional Transseptal Needle Versus Radiofrequency Energy Needle Puncture for Left Atrial Access (the TRAVERSE-ÅLA Study). <i>Journal of the American Heart Association</i> , 2013, 2, e000428.	3.7	52
12	Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion. <i>JAMA Cardiology</i> , 2021, 6, 1275.	6.1	49
13	Current and Future Use of Insertable Cardiac Monitors. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 1383-1396.	3.2	46
14	Safety of radiofrequency catheter ablation without coronary angiography in aortic cusp ventricular arrhythmias. <i>Heart Rhythm</i> , 2014, 11, 1117-1121.	0.7	43
15	Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1624-1638.	2.8	43
16	Risk Stratification for Arrhythmic Events in Patients With Asymptomatic Pre-Excitation: A Systematic Review for the 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. <i>Circulation</i> , 2016, 133, e575-86.	1.6	42
17	Differences in Anticoagulant Therapy Prescription in Patients with Paroxysmal Versus Persistent Atrial Fibrillation. <i>American Journal of Medicine</i> , 2015, 128, 654.e1-654.e10.	1.5	41
18	Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. <i>American Heart Journal</i> , 2018, 200, 24-31.	2.7	41

#	ARTICLE	IF	CITATIONS
19	Clinical Applications of Biomarkers in Atrial Fibrillation. American Journal of Medicine, 2017, 130, 1351-1357.	1.5	39
20	Predictors of an Inadequate Defibrillation Safety Margin at ICD Implantation. Journal of the American College of Cardiology, 2014, 64, 256-264.	2.8	32
21	Meta-analysis of the Usefulness of Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2021, 142, 66-73.	1.6	27
22	Differences in accessory pathway location by sex and race. Heart Rhythm, 2010, 7, 52-56.	0.7	26
23	Clinical and electrocardiographic characteristics of idiopathic ventricular arrhythmias with right bundle branch block and superior axis: Comparison of apical crux area and posterior septal left ventricle. Heart Rhythm, 2015, 12, 1137-1144.	0.7	25
24	Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. Clinical Pharmacology and Therapeutics, 2018, 104, 301-310.	4.7	25
25	Low Body Mass Index but Not Obesity Is Associated With In-Hospital Adverse Events and Mortality Among Implantable Cardioverter-Defibrillator Recipients: Insights From the National Cardiovascular Data Registry. Journal of the American Heart Association, 2012, 1, e003863.	3.7	24
26	Utilization trends and clinical outcomes in patients implanted with a single- vs a dual-coil implantable cardioverter-defibrillator lead: Insights from the ALTITUDE Study. Heart Rhythm, 2015, 12, 1770-1775.	0.7	23
27	Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk. Clinical Cardiology, 2018, 41, 1395-1402.	1.8	23
28	Oral Anticoagulant Prescription in Patients With Atrial Fibrillation and a Low Risk of Thromboembolism. JAMA Internal Medicine, 2015, 175, 1062.	5.1	21
29	Cardiac Resynchronization Defibrillator Therapy for Nonspecific Intraventricular Conduction Delay Versus Right Bundle Branch Block. Journal of the American College of Cardiology, 2019, 73, 3082-3099.	2.8	21
30	Meta-analysis of Effect of Modest (≈10%) Weight Loss in Management of Overweight and Obese Patients With Atrial Fibrillation. American Journal of Cardiology, 2019, 124, 1568-1574.	1.6	21
31	Adaptive cardiac resynchronization therapy is associated with decreased risk of incident atrial fibrillation compared to standard biventricular pacing: A real-world analysis of 37,450 patients followed by remote monitoring. Heart Rhythm, 2019, 16, 983-989.	0.7	21
32	Elevated pulmonary artery systolic pressures are associated with a lower risk of atrial fibrillation following lung transplantation. Journal of Electrocardiology, 2013, 46, 38-42.	0.9	20
33	Association of insurance type with receipt of oral anticoagulation in insured patients with atrial fibrillation: A report from the American College of Cardiology NCDR PINNACLE registry. American Heart Journal, 2018, 195, 50-59.	2.7	20
34	Left Atrial Appendage Electrical Isolation as a Target in Atrial Fibrillation. JACC: Clinical Electrophysiology, 2019, 5, 407-416.	3.2	20
35	Contemporary procedural trends of Watchman percutaneous left atrial appendage occlusion in the United States. Journal of Cardiovascular Electrophysiology, 2021, 32, 83-92.	1.7	20
36	Pericardial effusion requiring intervention in patients undergoing percutaneous left atrial appendage occlusion: Prevalence, predictors, and associated in-hospital adverse events from 17,700 procedures in the United States. Heart Rhythm, 2021, 18, 1508-1515.	0.7	20

#	ARTICLE	IF	CITATIONS
37	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	18
38	Harmonized outcome measures for use in atrial fibrillation patient registries and clinical practice. <i>Heart Rhythm</i> , 2019, 16, e3-e16.	0.7	18
39	Percutaneous left atrial appendage occlusion in atrial fibrillation patients with a contraindication to oral anticoagulation: a focused review. <i>Europace</i> , 2018, 20, 1412-1419.	1.7	17
40	Computational ECG mapping and respiratory gating to optimize stereotactic ablative radiotherapy workflow for refractory ventricular tachycardia. <i>Heart Rhythm O2</i> , 2021, 2, 511-520.	1.7	17
41	Predictors of Axillary Vein Location for Vascular Access during Pacemaker and Defibrillator Lead Implantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 1585-1592.	1.2	16
42	Risk stratification for arrhythmic events in patients with asymptomatic pre-excitation: A systematic review for the 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia. <i>Heart Rhythm</i> , 2016, 13, e222-e237.	0.7	16
43	Role of adjunctive posterior wall isolation in patients undergoing atrial fibrillation ablation: a systematic review and meta-analysis. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 58, 77-86.	1.3	16
44	Racial Disparities in In-Hospital Adverse Events Among Patients With Atrial Fibrillation Implanted With a Watchman Left Atrial Appendage Occlusion Device: A US National Perspective. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009691.	4.8	16
45	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. <i>American Journal of Cardiology</i> , 2018, 121, 131-140.	1.6	15
46	Anticoagulation in patients with atrial fibrillation and heart failure: Insights from the NCDR PINNACLE-AF registry. <i>Clinical Cardiology</i> , 2019, 42, 339-345.	1.8	15
47	Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 20-28.	3.2	14
48	Association of chronic kidney disease and end-stage renal disease with procedural complications and in-hospital outcomes from left atrial appendage occlusion device implantation in patients with atrial fibrillation: Insights from the national inpatient sample of 36,065 procedures. <i>Heart Rhythm O2</i> , 2021, 2, 472-479.	1.7	14
49	The Occurrence of Implantable Cardioverter Defibrillator Therapies After Generator Replacement in Patients Who No Longer Meet Primary Prevention Indications. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 724-729.	1.7	13
50	Outcomes following implantable cardioverter-defibrillator generator replacement in patients with recovered left ventricular systolic function: The National Cardiovascular Data Registry. <i>Heart Rhythm</i> , 2019, 16, 733-740.	0.7	13
51	Comparison of Outcomes After Ablation of Atrial Fibrillation in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2020, 136, 62-70.	1.6	13
52	P2Y ₁₂ inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis. <i>Heart</i> , 2020, 106, 575-583.	2.9	13
53	Procedure timing as a predictor of in-hospital adverse outcomes from implantable cardioverter-defibrillator implantation: Insights from the National Cardiovascular Data Registry. <i>American Heart Journal</i> , 2015, 169, 45-52.e3.	2.7	12
54	Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry. <i>Heart Rhythm</i> , 2018, 15, 847-854.	0.7	12

#	ARTICLE	IF	CITATIONS
55	Impact of a 4q25 Genetic Variant in Atrial Flutter and on the Risk of Atrial Fibrillation After Cavotricuspid Isthmus Ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 271-277.	1.7	11
56	Cardiac Device Implant Skin Closure with a Novel Adjustable, Coaptive Tape-Based Device. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 1077-1082.	1.2	11
57	The Heart Rhythm Society/American College of Physicians Atrial Fibrillation Screening and Education Initiative. <i>Heart Rhythm</i> , 2019, 16, e59-e65.	0.7	11
58	Complete heart block and subsequent sudden cardiac death from immune checkpoint inhibitor-associated myocarditis. <i>HeartRhythm Case Reports</i> , 2020, 6, 761-764.	0.4	11
59	Reversal agents for direct oral anticoagulants: A focused review. <i>International Journal of Cardiology</i> , 2016, 223, 244-250.	1.7	10
60	Factors associated with rhythm control treatment decisions in patients with atrial fibrillation—Insights from the NCDR PINNACLE registry. <i>American Heart Journal</i> , 2017, 187, 88-97.	2.7	10
61	Electrical Substrate Ablation for Refractory Ventricular Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e008868.	4.8	10
62	In vivo porcine characterization of atrial lesion safety and efficacy utilizing a circular pulsed-field ablation catheter including assessment of collateral damage to adjacent tissue in supratherapeutic ablation applications. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, 33, 1480-1488.	1.7	10
63	Antithrombotic regimens in patients with atrial fibrillation and coronary artery disease after percutaneous coronary intervention: A focused review. <i>International Journal of Cardiology</i> , 2017, 243, 263-269.	1.7	9
64	Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2019, 123, 187-195.	1.6	9
65	Ablation of mitral annular flutter ablation utilizing a left atrial anterior line versus a lateral mitral isthmus line: a systematic review and meta-analysis. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 63, 87-95.	1.3	9
66	Trainee inexperience is associated with longer procedure times but no increase in complications for cardiac device implantation. <i>Heart Rhythm</i> , 2013, 10, 1755-1758.	0.7	8
67	Arrhythmia care in a value-based environment: Past, present, and future. <i>Heart Rhythm</i> , 2018, 15, e5-e15.	0.7	8
68	Clinical and Laboratory Improvement in Hyperadrenergic Postural Orthostatic Tachycardia Syndrome (POTS) after COVID-19 Infection. <i>Case Reports in Cardiology</i> , 2021, 2021, 1-3.	0.2	8
69	Predictors of Fluoroscopy Time and Procedural Failure During Biventricular Device Implantation. <i>American Journal of Cardiology</i> , 2012, 110, 240-245.	1.6	7
70	The Smartwatch Will See You Now. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1433-1434.	2.8	7
71	Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. <i>JAMA Network Open</i> , 2019, 2, e1913553.	5.9	7
72	Fasciculoventricular and atrioventricular accessory pathways in patients with Danon disease and preexcitation: A multicenter experience. <i>Heart Rhythm</i> , 2021, 18, 1194-1202.	0.7	7

#	ARTICLE	IF	CITATIONS
73	Association of heart failure with procedural complications and in-hospital outcomes from left atrial appendage occlusion device implantation in patients with atrial fibrillation: insights from the national inpatient sample of 62,980 procedures. <i>Europace</i> , 2022, 24, 1451-1459.	1.7	7
74	Consideration of patient age and life expectancy in implantable cardioverter-defibrillator referral. <i>American Heart Journal</i> , 2013, 166, 164-170.e5.	2.7	6
75	Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review. <i>Clinical Cardiology</i> , 2015, 38, 684-691.	1.8	6
76	Concealed Accessory Pathways with a Single Ventricular and Two Discrete Atrial Insertion Sites. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 255-263.	1.2	6
77	Long-term mode and timing of premature ventricular complex recurrence following successful catheter ablation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019, 55, 153-160.	1.3	6
78	Ventricular arrhythmias in patients with biventricular assist devices. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 58, 243-252.	1.3	6
79	Association of advanced age with procedural complications and in-hospital outcomes from left atrial appendage occlusion device implantation in patients with atrial fibrillation: insights from the National Inpatient Sample of 36,065 procedures. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 65, 219-226.	1.3	6
80	Coronary Venous Dissection from Left Ventricular Lead Placement During Cardiac Resynchronization Therapy With Defibrillator Implantation and Associated in-Hospital Adverse Events (from the NCDR ICD) <i>Tj ETQq0 0.0rgBT /Oylock 10</i>	1.0	5
81	Characteristics and outcomes of recurrent atrial fibrillation after prior failed pulmonary vein isolation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 64, 715-722.	1.3	5
82	Predictors of Unusual ECG Characteristics in Cavotricuspid Isthmus-Dependent Atrial Flutter Ablation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 1251-1257.	1.2	4
83	Compatibility of Radiofrequency Surgical Sponge Detection Technology with Cardiac Implantable Electronic Devices and Temporary Pacemakers. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 1254-1260.	1.2	4
84	Successful ventricular tachycardia ablation in a patient with a biventricular ventricular assist device and heparin-induced thrombocytopenia using bivalirudin. <i>HeartRhythm Case Reports</i> , 2018, 4, 367-370.	0.4	4
85	Prevalence, predictors and complications with defibrillation threshold testing in pediatric patients: Results from the NCDR. <i>International Journal of Cardiology</i> , 2020, 305, 44-49.	1.7	4
86	Association between early recurrences of atrial tachyarrhythmias and long-term outcomes in patients after repeat atrial fibrillation ablation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 64, 323-331.	1.3	4
87	Outpatient Prescription Practices in Patients with Atrial Fibrillation (From the NCDR PINNACLE) <i>Tj ETQq1 1 0.784314rgBT /Oylock 10</i>	1.6	4
88	Cardiovascular implantable electronic device therapy in patients with left ventricular assist devices: insights from TRAViATA. <i>International Journal of Cardiology</i> , 2021, 340, 26-33.	1.7	4
89	Performance and acute procedural outcomes of the EnSite Precision [®] cardiac mapping system for electrophysiology mapping and ablation procedures: results from the EnSite Precision [®] observational study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 65, 141-151.	1.3	4
90	Colchicine After Pulmonary Vein Isolation to Prevent the Early Recurrence of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1797-1798.	2.8	3

#	ARTICLE	IF	CITATIONS
91	Valvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3360-3361.	2.8	3
92	Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. <i>International Journal of Cardiology</i> , 2020, 321, 88-94.	1.7	3
93	Clinical factors associated with baseline history of atrial fibrillation and subsequent clinical outcomes following initial implantable cardioverter-defibrillator placement. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 542-550.	1.2	3
94	Comparison of left ventricular lead upgrade vs continued medical care among patients eligible for cardiac resynchronization therapy at the time of defibrillator generator replacement: Predictors of left ventricular lead upgrade and associations with long-term outcomes. <i>Heart Rhythm</i> , 2020, 17, 1878-1886.	0.7	3
95	Intraluminal Esophageal Temperature Monitoring Using the CircaS-Cath [™] Temperature Probe to Guide Left Atrial Ablation in Patients with Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2020, 13, 2386.	0.5	3
96	Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database. <i>PLoS ONE</i> , 2022, 17, e0263903.	2.5	3
97	Association between implantable cardioverter-defibrillator and survival in patients awaiting heart transplantation: A meta-analysis and systematic review. <i>Heart Rhythm O2</i> , 2021, 2, 710-718.	1.7	3
98	Esophageal Temperature Monitoring During AF Ablation: Multi-Sensor or Single-Sensor Probe?. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, E24.	1.7	2
99	Reply. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2493.	2.8	2
100	Natriuretic Peptides for Predicting Left Atrial Reverse Remodeling After Atrial Fibrillation Ablation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 159-161.	3.2	2
101	A surgeon with symptomatic ventricular tachycardia while operating and exacerbated by left lateral decubitus position: Too much of a stretch?. <i>HeartRhythm Case Reports</i> , 2017, 3, 210-214.	0.4	2
102	Cardiac Tamponade From Permanent Pacemaker Implantation. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 47-49.	3.2	2
103	Randomized controlled trial of Amigo [®] robotically controlled versus manually controlled ablation of the cavo-tricuspid isthmus using a contact force ablation catheter. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 51, 125-132.	1.3	2
104	Ventricular Tachycardia Storm Originating From Moderator Band Requiring Extracorporeal Membrane Oxygenation. <i>JACC: Case Reports</i> , 2020, 2, 946-950.	0.6	2
105	Effect of closed loop stimulation versus accelerometer on outcomes with cardiac resynchronization therapy: the CLASS trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 61, 479-485.	1.3	2
106	Association between specific antiarrhythmic drug prescription in the post-procedural blanking period and recurrent atrial arrhythmias after catheter ablation for atrial fibrillation. <i>PLoS ONE</i> , 2021, 16, e0253266.	2.5	2
107	Defibrillation Safety Margin Testing in Patients With Congenital Heart Disease. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 1145-1154.	3.2	2
108	A Cautionary Tone Before Expanded Adoption of the Proposed CHA2DS2-VASc R Score. <i>Journal of the American College of Cardiology</i> , 2017, 69, 251.	2.8	1

#	ARTICLE	IF	CITATIONS
109	The Relationship of Antitachycardia Pacing versus Shock in an Implantable Cardioverter-Defibrillator Population and the Risk of Mortality: Just an Association?. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 423-424.	1.7	1
110	Reasons for and predictors of acute hospitalization versus elective outpatient implantable cardioverter-defibrillator implantation and subsequent differential clinical outcomes. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 85-93.	1.3	1
111	Predictors of rate-adaptive pacing in patients implanted with implantable cardioverter-defibrillator and subsequent differential clinical outcomes. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019, 55, 83-91.	1.3	1
112	Clinical implications of redefining recurrence of atrial fibrillation following catheter ablation. <i>Europace</i> , 2019, 21, 1139-1139.	1.7	1
113	Association of body mass index with cardiac resynchronization therapy intention and left ventricular lead implantation failure: insights from the NCDR implantable cardioverter-defibrillator registry. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 57, 279-288.	1.3	1
114	Left Atrial Appendage Triggers in Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 31-33.	3.2	1
115	Atrial fibrillation in patients with heart failure with preserved ejection fraction. <i>Current Opinion in Cardiology</i> , 2020, 35, 260-270.	1.8	1
116	A simple improvement on existing technology to enhance transeptal puncture and left atrial access using large diameter sheaths for mapping, ablation, and LAA occlusion procedures. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 735-736.	1.7	1
117	Catheter Ablation for Hospitalized Atrial Fibrillation Patients with Reduced Systolic Function: Analysis of Inpatient Mortality, Resource Utilization and Complications. <i>Journal of Atrial Fibrillation</i> , 2021, 13, 2480.	0.5	1
118	An Unusual Case of Pacemaker Malfunction. <i>Cardiac Electrophysiology Clinics</i> , 2010, 2, 285-288.	1.7	0
119	Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2700-2701.	2.8	0
120	Overtreatment of Low-Risk Patients With Atrial Fibrillation—The Quality Coin Has 2 Sides—Reply. <i>JAMA Cardiology</i> , 2016, 1, 849.	6.1	0
121	Benefits of Contemporary Implantable Cardioverter Defibrillators in Patients With Improved Ejection Fraction: When Is the Most Clinically Relevant Time to Evaluate?. <i>JAMA Cardiology</i> , 2017, 2, 1397.	6.1	0
122	Beyond Pulmonary Vein Isolation During Catheter Ablation in Atrial Fibrillation and Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1292-1293.	2.8	0
123	Response to: "Enlisting Emergency Medicine Clinicians to Help Reduce Strokes in High-Risk Patients With Atrial Fibrillation and Flutter". <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 615-615.	4.7	0
124	Letter by Aldaas et al Regarding Article, "Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study". <i>Circulation</i> , 2019, 139, 144-145.	1.6	0
125	Spontaneous Left Atrial Thrombus Formation on the Catheter Delivery System During WATCHMAN Implantation. <i>JACC: Case Reports</i> , 2020, 2, 444-448.	0.6	0
126	Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry. <i>JAMA Network Open</i> , 2021, 4, e2035470.	5.9	0

#	ARTICLE	IF	CITATIONS
127	Successful use of a prophylactic cerebral protection device via the radial artery during left atrial appendage occlusion device implantation in a patient with a mitral valve mass. HeartRhythm Case Reports, 2021, 7, 242-245.	0.4	0
128	Atrial fibrillation associated with heart failure treated by a 2-lead CRT-DX system (BIO-AffectDX): Study design and clinical protocol. Heart Rhythm O2, 2021, 2, 642-650.	1.7	0
129	To Occlude or Not to Occlude the Left Atrial Appendage in Womenâ€™Reply. JAMA Cardiology, 2022, , .	6.1	0